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followed by Italy, Spain and Hungary ahead of a group of six countries of about
equal impact. When weighing edges between countries by market size the picture
changed somewhat with Germany still the most important country ahead of Italy,
UK, France and Spain. CONCLUSIONS: Taking the entire web of price referencing
relationships into consideration provides somewhat different conclusions than
just counting the number of countries referencing a single country when assessing
the importance of that particular country. Likewise, when incorporating the mar-
ket size of each country, this gives a different result than just ranking countries by
market size alone.
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OBJECTIVES: Many states have implemented prescription drug monitoring pro-
grams (PDMPs) to address abuse and diversion of controlled substances. While the
perceptions of prescribers and dispensers have been examined, the patient per-
spective on PDMPs is notably absent from existing research. This project examined
patient perceptions of Kentucky’s PDMP by asking Medicaid beneficiaries about
their experienceswith the Kentucky All Schedule Prescription Electronic Reporting
program (KASPER). METHODS: Medicaid beneficiaries over age 18 were contacted
by mail to complete a modified version of the Consumer Assessment of Health
Plans Survey. A reminder postcard and second survey was sent to non-responders
two weeks after the first mailing. 1,305 surveys were returned (n5,297, response
rate24.64%). Responses were coded and 25% of surveys were re-coded to test
inter-coder reliability. Statistical analysis was conducted in STATA v11.0.
RESULTS: Of 461 respondents, 63 (13.67%) reported that their health care provider
had discussed their KASPER report with them. Fewer respondents reported that
KASPER prevented them from getting (8.11%) or filling (8.53%) a prescription. Pa-
tients with chronic pain conditions weremore likely to have a health care provider
discuss a KASPER report with them (10.18%) than non-chronic pain patients
(3.95%). Chronic pain patients were also more likely to report that a KASPER report
prevented them from getting a prescription than non-chronic pain patients (6.01%
vs. 1.75%). Chi-square testing demonstrates that these differences are statistically
significant (discussed KASPER report p0.006; KASPER report prevented getting
prescription p0.013). There were limited differences in patient-reported experi-
ences with KASPER based upon patient gender, race, Hispanic ethnicity, or educa-
tion level. CONCLUSIONS: Most respondents report they are unaffected by the
KASPER program. Respondents with chronic pain are significantly more apt to
report difficulty getting and filling prescriptions. States seeking to form or alter
PDMPs should consider patient input as well as prescriber and dispenser opinions.
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OBJECTIVES: To examine whether R&D for medical products differs from other
forms of R&D and should therefore be guided by different policy solutions in at-
tempting to stimulate it.METHODS: Conceptual analysis and regression analysis.
RESULTS:We argue that, as opposed to standard products, there is a link between
output markets and devlopment of medical products in the sense that the cost
developing newmedical products depends on the quality and price of conventional
care in output markets. This is because clinical trials are the major driver of devel-
opment costs and that recruitment of subjects into trials requires them to forego
conventional care. This output market link induces non-standard effects on med-
ical R&D costs and innovative returns. First, medical R&D has a self-limiting effect
because high quality innovationsmake future developmentmore difficult through
prolonged recruitment. Second, outputmarket policies, such as universal coverage
and price controls, have not only demand-side effects on R&D, but also supply side
effects by altering the cost of development. Third, in contrast with other product
markets, the development spending in a country may not be driven by its relative
R&D talent but by output market policies. We consider evidence of the discussed
link between output markets and development for the break-through HIV thera-
pies introduced on the market in 1996. We document a dramatic drop of 35% in
yearly trial recruitment induced by these new innovations, slowing down develop-
ment and lowering innovative returns. CONCLUSIONS: We argue that the the fu-
ture efficinecy analysis of various forms of health policy in output markets should
be evaluated in terms of how it affects development incentives.
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OBJECTIVES: Montelukast has been approved for the prophylaxis and chronic
treatment of asthma in patients 12months and older, acute prevention of exercise
induced bronchospasm in patients 15 years and older and relief of symptoms of
seasonal and perennial allergic rhinitis in patients as young as 6 months. We
examined trends inmontelukast use, new use, and on-label and off-label use from
1998 to 2008. METHODS: In this retrospective cohort study of administrative
claims, eligible subjects in the Lifelink database between January 1997 and Decem-
ber 2009 were analyzed. Study subjects had to be continuously enrolled for two
years. On label use was determined by searching for ICD-9-CM codes for approved
indications; asthma, exercise induced bronchospasm, and allergic rhinitis. OLS
regression was used to assess linear trends over time. RESULTS: 0.16% of subjects
were prescribed montelukast in 1998 and 2.44% in 2008 and the linear trend of
increase in use was significant (R20.978, p0.0001). 37,793 subjects were eligible
for the analysis of off-label usewith amean age of 31.22 years and 43.6%weremale.
Off-label use was lowest in 1999 (12.56%) and highest in 2007 (24.54%) with a sig-
nificant increasing trend (R20.5776, p0.0066) but it increased more modestly
from 2002 (20.6%) to 2008 (23.91%). Overall 23.02% of subjects usedmontelukast off
label and the elderly (31.45%) and persons from the south (28.16%) had the highest
rates of montelukast off label use. CONCLUSIONS: Montelukast prescribing in-
creased substantially over the previous decade where in 2008, 1 in 40 persons with
commercial insurance had at least one prescription filled. Over three quarters of
montelukast prescribing is supported by a diagnosis for a labeled indication. Off
label use is greatest in the elderly which may be partially explained by more evi-
dence based off label uses in the literature for adults.
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OBJECTIVES:Understanding the characteristics and distribution of inpatients who
have basic medical insurance within China, Analyzing the treatment status and
inpatients’ expenses, Studying and summarizing the application of various kinds
of medication, Providing database to government for supporting drug regulatory
policy .METHODS:We conducted a sampling survey of inpatients with basic med-
ical insurance in all the provinces in China by city. In 2010, we extracted data of
157,577 inpatients, and accounting for 0.5% of the total sample size. The sampled
data was statistically analyzed by SQL Server 2003. RESULTS: Average hospital
expenses per visit increased rapidly while drug expenses remained high. In 2009,
the average hospital expense of inpatients with basic medical insurance reached
RMB7,670 Yuan per visit, a 13.6% increased from the previous year. The drug ex-
pense was accounted for 49.1% of the total. Overall the spectrum of diseases of
inpatients is stable while the proportion of tumor patients was increasing. In 2009,
among those inpatients afflicted by various diseases, the Cardiovascular system
diseases accounted for 26.75%, which still kept the first position, and Tumors ac-
counted for 12.35% (10.95% in 2008). CONCLUSIONS: 1)Effects from the aging pop-
ulation, the health insurance fund spentmostly on the elderly, aremore obvious. In
2009, among urban basic medical insured people, inpatients that are over sixty
accounted for 49.2%, with 55.26% of the total expense. 2) The Medical Insurance
Fundhad a high concentration of resource use. In 2009, 9.3% of the drugs accounted
for 80% the total drug expense. 3) The rational use of drugs is not optimistic. The
expense of antibiotic medicines accounted for 29.3% of the total expense of chem-
ical medicines, the number of the inpatients that have taken conbinational antibi-
otics accounted for 63.7% of the total inpatients. Abuse of Traditional-Chinese-
Medicine-injection and drugs for adjuvant-treatment also needs to be monitored.
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OBJECTIVES: To examine the association of self-reported health status with cost-
related medication nonadherence (CRN), as well as with prescription drug out-of-
pocket spending (OOP) among senior Medicare enrollees.METHODS:We analyzed
the 2008 Health and Retirement Study (HRS), a national survey of adults aged 50 or
older. Self-reported health status was classified into three categories: excellent
(excellent and very good), good, and poor (fair and poor) health. We estimated the
association between self-report health status and 1) cost-related medication non-
adherence using Logistic regression; 2) monthly out-of-pocket pharmacy spending
using generalized linearmodel (GLM) controlling for socio-demographic character-
istics and physical health conditions. All estimates were weighted to be nationally
representative. RESULTS: Among 9,090 Medicare beneficiaries aged 65 or older
(mean age 74.7 years), 56.1% were female, 5.8% reported taking less medication
because of cost. Compared to those with excellent health status, beneficiaries with
good health (OR1.643, p0.0001, 95% confidence interval [CI] 1.263-2.138) and
poor health (OR2.947, p0.0001, 95% CI 2.264-3.834) were more likely to report
cost-related medication nonadherence. The GLM regression results showed that
compared to excellent health beneficiaries, the average monthly out-of-pocket
pharmacy spending was $13.844 (p0.0001, 95% CI 7.500-20.186) higher for good
health and $27.245 (p0.0001, 95%CI 17.695-36.794) higher for poor health subjects.
CONCLUSIONS:Drug spending is heavily concentrated among individuals 65 years
or older and cost-relatedmedication underuse among seniors has been a big public
health concern, especially before the implementation of Medicare Part D in 2006.
This study find that worse health status is significantly associated with increased
likelihood of cost-related medication nonadherence and higher out-of-pocket ex-
penditures for prescription drugs. Senior Medicare beneficiaries with poor health
still faced higher OOP burden compared with their healthy counterparts.
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OBJECTIVES: With the January 2006 introduction of Medicare Part D Plans (PDP)
intended to increase drug access, we hypothesized that it would impact trends in
prescription volume (TRx) and out-of-pocket costs (OPC). We evaluated these un-
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